PubMed Health⌕ Search

Biomedical subjects

H Toki

Publications and source records attributed to H Toki.

99 records · Page 6Linked to original sources
PubMed1976

A case of smoldering acute leukemia: long survival duration of 3 years and 9 months after the diagnosis.

A typical case of smoldering acute leukemia has been followed up for long-standing course. This 73 year-old woman survived 3 years and 9 months after diagnosis of acute myelogenous leukemia. The hematological study on admission showed hypoplastic bone marrow with 51.6% of abnormal myeloblasts, although a few myeloblasts were seen in the peripheral blood. Intensive anti-leukemia chemotherapy was withheld during the whole course except on the terminal acute phase. Three episodes of pneumonia occurred and then, the proliferation of leukemic cells subsided concomitnantly after the exacerbation of infection. The direct and/or host-mediated anti-tumor effect by infectious organism was suggestive in this case. The labeling index with 3H-TdR of leukemic cells was 4.9%, suggesting the slow multiplication. Positive tuberculin reactivity and normal ratio of lymphocyte blastogenesis confirmed the preserved cellular immunity. These factors might be considered to be closely related with the smoldering course of this particular case.

Aged↗
PubMed1976

Direct implantation of Ph1 chromosome-positive myeloblasts into newborn hamsters.

Peripheral leukocytes from a male patient with chronic myelogenous leukemia in blast crisis were implanted directly into the intraperitoneal cavity of seven newborn hamsters treated with antilymphocyte serum. At sacrifice 17-19 days after implantation, three hamsters were found to have disseminated tumors. The other four hamsters were cannibalized. Chromosome analysis of cells from the enlarged lymph nodes revealed the presence of a human male karyotype. Most metaphase cells were pseudodiploid with the Ph1 chromosome and isochromosome 17, while a few metaphase cells were classically diploid. Identical chromosome constitutions were observed in the original peripheral leukocytes of the patient. The results strongly suggested simultaneous heterotransplantation of Ph1-positive leukemic and normal leukocytes.

Animals↗
PubMedDate not supplied

Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.

The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver. After the oily carcinostatic agents were administered by Lp-TAE, HT, at a temperature of greater than 42.5 degrees C, was induced for 40 min, twice a week by an RF of 8 MHz for a total of 10 to 38 times. The response rate was 40% in the 10 cases that were treated with Lp-TAE combined with HT and 20% in the 10 cases that were treated with Lp-TAE. The patients who were treated with Lp-TAE combined with HT had a tendency to have better survival rates than those of the Lp-TAE group (p less than 0.099). The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.

Aged↗
PubMedDate not supplied

A phase II study of epirubicin in acute leukemia: a cooperative group study.

A new doxorubicin analogue, epirubicin (EPI), was evaluated in 41 patients with acute leukemia at 11 Japanese institutions participating in a phase II study between January 1983 and July 1985; during this period 35 patients were considered evaluable. There were 25 males and 10 females with a median age of 43 years (range, 19-71 years) and the median PS of 2 (range, 0-4). EPI was given to 25 patients who had previously been treated with intensive combination chemotherapy, of whom 22 had already received anthracyclines. Ten patients had not been treated previously. Two dose schedules were explored. The higher dose schedule (18 cases) consisted of the administration of 24 to 60 mg/m2 for 3 to 5 consecutive days, and the lower dose schedule (17 cases) consisted of 11 to 20 mg/m2 for 5 to 7 days. Remissions were obtained in 7 patients (20%), 2 of whom showed complete remission and 5 partial remission. The remission duration was 2, 2, 3, 5, 16, 16 and 29+ weeks, respectively. The expected myelosuppression was universal. Stomatitis occurred in 15 patients, of which 7 cases were severe. This stomatitis occurred frequently in the higher dose schedule, and was thought to be a dose-limiting factor. In others, alopecia, G.I. symptoms, and diarrhoea (4 patients) were seen. These results from a cooperative group study indicated that EPI was an effective drug for the treatment of acute leukemia.

Acute Disease↗